These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 35841237)

  • 61. Drug Development for Psychotropic, Cognitive-Enhancing, and Disease-Modifying Treatments for Alzheimer's Disease.
    Cummings J
    J Neuropsychiatry Clin Neurosci; 2021; 33(1):3-13. PubMed ID: 33108950
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Thioredoxin-interacting protein (TXNIP) as a target for Alzheimer's disease: flavonoids and phenols.
    Zhang M; Hu G; Shao N; Qin Y; Chen Q; Wang Y; Zhou P; Cai B
    Inflammopharmacology; 2021 Oct; 29(5):1317-1329. PubMed ID: 34350508
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Methodologies Related to Computational Models in View of Developing Anti-Alzheimer Drugs: An Overview.
    Baheti K; Kale M
    Curr Drug Discov Technol; 2019; 16(1):66-73. PubMed ID: 29663890
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Research and development challenges for Alzheimer's disease drug discovery.
    Krafft GA
    Neurobiol Aging; 1994; 15 Suppl 2():S57-9. PubMed ID: 7700463
    [No Abstract]   [Full Text] [Related]  

  • 65. The need to show minimum clinically important differences in Alzheimer's disease trials.
    Liu KY; Schneider LS; Howard R
    Lancet Psychiatry; 2021 Nov; 8(11):1013-1016. PubMed ID: 34087114
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Protein-Protein Interactions and Aggregation Inhibitors in Alzheimer's Disease.
    Ganeshpurkar A; Swetha R; Kumar D; Gangaram GP; Singh R; Gutti G; Jana S; Kumar D; Kumar A; Singh SK
    Curr Top Med Chem; 2019; 19(7):501-533. PubMed ID: 30836921
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Editorial: cytokine inhibition for treatment of Alzheimer's disease.
    Rosenberg PB
    MedGenMed; 2006 Apr; 8(2):24. PubMed ID: 16926763
    [No Abstract]   [Full Text] [Related]  

  • 68. Acetylcholinesterase inhibitors for the treatment of Alzheimer's disease - a patent review (2016-present).
    Bortolami M; Rocco D; Messore A; Di Santo R; Costi R; Madia VN; Scipione L; Pandolfi F
    Expert Opin Ther Pat; 2021 May; 31(5):399-420. PubMed ID: 33428491
    [No Abstract]   [Full Text] [Related]  

  • 69. 2-Propargylamino-naphthoquinone derivatives as multipotent agents for the treatment of Alzheimer's disease.
    Mezeiova E; Janockova J; Andrys R; Soukup O; Kobrlova T; Muckova L; Pejchal J; Simunkova M; Handl J; Micankova P; Capek J; Rousar T; Hrabinova M; Nepovimova E; Marco-Contelles JL; Valko M; Korabecny J
    Eur J Med Chem; 2021 Feb; 211():113112. PubMed ID: 33360800
    [TBL] [Abstract][Full Text] [Related]  

  • 70. US, EU, and Japanese Regulatory Guidelines for Development of Drugs for Treatment of Alzheimer's Disease: Implications for Global Drug Development.
    Morant AV; Vestergaard HT; Lassen AB; Navikas V
    Clin Transl Sci; 2020 Jul; 13(4):652-664. PubMed ID: 32043310
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The P2X7 receptor: a new therapeutic target in Alzheimer's disease.
    Illes P; Rubini P; Huang L; Tang Y
    Expert Opin Ther Targets; 2019 Mar; 23(3):165-176. PubMed ID: 30691318
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Alzheimer's disease: new approaches to drug discovery.
    Bolognesi ML; Matera R; Minarini A; Rosini M; Melchiorre C
    Curr Opin Chem Biol; 2009 Jun; 13(3):303-8. PubMed ID: 19467915
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Editorial: Establishing a Trial Ready Cohort to Accelerate Alzheimer's Clinical Trial Enrollment and Treatments.
    Meyers EA; Carrillo MC
    J Prev Alzheimers Dis; 2020; 7(4):202-203. PubMed ID: 32920618
    [No Abstract]   [Full Text] [Related]  

  • 74. New evidence for dual binding site inhibitors of acetylcholinesterase as improved drugs for treatment of Alzheimer's disease.
    Zueva I; Dias J; Lushchekina S; Semenov V; Mukhamedyarov M; Pashirova T; Babaev V; Nachon F; Petrova N; Nurullin L; Zakharova L; Ilyin V; Masson P; Petrov K
    Neuropharmacology; 2019 Sep; 155():131-141. PubMed ID: 31132435
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Editorial: Multitarget Molecules for Alzheimer's Disease Therapy.
    Marco-Contelles J; Fall Y
    Curr Top Med Chem; 2017; 17(31):3318. PubMed ID: 29500890
    [No Abstract]   [Full Text] [Related]  

  • 76. Have there been improvements in Alzheimer's disease drug discovery over the past 5 years?
    Cacabelos R
    Expert Opin Drug Discov; 2018 Jun; 13(6):523-538. PubMed ID: 29607687
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Role of GPR40 in pathogenesis and treatment of Alzheimer's disease and type 2 diabetic dementia.
    Chen JJ; Gong YH; He L
    J Drug Target; 2019 Apr; 27(4):347-354. PubMed ID: 29929407
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Is a potential Alzheimer's therapy already in use for other conditions? Can medications for hypertension, diabetes and acne help with the symptoms?
    Corbett A; Ballard C
    Expert Opin Investig Drugs; 2013 Aug; 22(8):941-3. PubMed ID: 23808708
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Benzofuran and Indole: Promising Scaffolds for Drug Development in Alzheimer's Disease.
    Goyal D; Kaur A; Goyal B
    ChemMedChem; 2018 Jul; 13(13):1275-1299. PubMed ID: 29742314
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cholinesterase as a Target for Drug Development in Alzheimer's Disease.
    Sharma P; Tripathi MK; Shrivastava SK
    Methods Mol Biol; 2020; 2089():257-286. PubMed ID: 31773661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.